- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02281838
The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II (ICH-ADAPT II)
The vast majority of intracerebral hemorrhage (ICH) patients present with elevated blood pressure(BP). Management of BP is controversial with two competing rationales. There is some evidence that hyperacute treatment may improve outcomes by reducing the rate of hematoma expansion. Physicians have been reluctant to reduce BP early after ICH onset, fearing reduced cerebral blood flow (CBF) will increase ischemia and increase the risk of further damage. Other confounding mediators to further ischemic injury following ICH include increased platelet activity, withdrawal of antithrombotic therapy, endothelial dysfunction, inflammation and hypercoagulability.
This study is phase II of the ICH-ADAPT study. The investigators hypothesize that aggressive antihypertensive therapy will alter the natural history of heamatoma growth, improving outcomes after Intracranial Hemorrhage (ICH). The previous phase I ICH-ADAPT study has established the safety of early BP treatment.
The investigators have designed a phase II study in which ICH patients are randomized to aggressive versus conservative BP treatment using a deferred consent procedure. An adaptive randomization will be used to treat BP to < 140 mmHg SBP or < 180 mmHg SBP. Treatment must be implemented as soon as possible after radiological confirmation of diagnosis. Antihypertensive therapy must begin within 6 hours of symptom onset. The patient will be re-imaged 24 hours later. The patient will have continuous non-invasive BP and heart rate(HR) monitoring for a minimum of 24 hours. Antihypertensive drug use and dosage will be recorded with BP and HR. Patients will be monitored regularly until study completion. MRI's will be done at 48 hours, day 7 and day 30. This imaging will help to detect ischemic changes that may occur. Blood will be collected at the same time as the MRI. Blood analysis will be done to possibly identify biomarkers that may be putative mediators of ischemic injury in ICH patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design: multi-centre randomized open-label, blinded-endpoint trial of two different BP management strategies. This study is being conducted in the Emergency Departments and Stroke Units of Canadian academic and non-academic centres.
Overall Aim and Hypothesis: The primary study aim is to assess the rate of ischemic lesion development in patients randomized to two different BP treatment strategies. The overall a priori hypothesis is that aggressive BP reduction will not be associated with ischemic injury after ICH.
Patients: Male and female patients will be recruited from Emergency Departments of participating hospitals. A total of 270 patients will be included over 3 years.
Baseline Data and Randomization: Demographics, Glasgow Coma Scale (GCS) and National Institutes of Health Stroke Scale (NIHSS) scores (both of which are part of routine stroke patient assessment), time of symptom onset and diagnostic CT scan will all be recorded. If the CT scan is completed within 6 hours of onset and confirms evidence of a primary ICH, patients will be randomized. Where patients are incompetent and surrogate decision makers are not immediately available, randomization will occur using a deferred consent procedure. Stroke risk factors, past medical history and medications, with emphasis on antihypertensives, as well as standard clinical blood work (complete blood count and coagulation profile) will be recorded after randomization in order to avoid delays to BP treatment.
Intervention - Blood Pressure Management Protocols:
"Aggressive" BP Target (<140 mmHg) Treatment Group: Patients randomized to the <140 mmHg group (n=135) will immediately receive a 10 mg IV bolus of labetalol, administered over 1 minute. A protocol designed to achieve and maintain systolic BP <140 mmHg within 60 minutes of randomization has been designed (Appendix 5). A key feature of this protocol is the utilization of IV enalapril, which can be given regularly (Q. 6 hourly), avoiding BP fluctuations, a problem which has been noted previously when using bolus-based protocols.109 Patients randomized to the <140 mmHg group will be treated with 1.25 mg of IV enalapril immediately after labetalol administration. A lower limit of 120 mmHg has been stipulated, although given the investigators experience in ICH ADAPT I, this is unlikely to be achieved. In the event of systolic BP falling below 120 mmHg, antihypertensive therapy will be held and patients will be fluid resuscitated with isotonic saline. Pressor agents will not be used.
"Conservative" BP Target (<180 mmHg) Treatment Group: Patients randomized to the <180 mmHg group (n=135) will be administered parenteral antihypertensive therapy only if systolic BP is ≥180 mmHg, consistent with current guidelines.
All patients will have continuous non-invasive BP and heart rate (HR) monitoring for a minimum of 24h. BP and HR will be recorded most intensively during the hyperacute phase, as per the NINDS r-tPA protocol for vital signs monitoring. Antihypertensive drug use and dosages will be recorded concomitantly with BP and HR. Patients will be monitored regularly until study completion. Door-to-needle times will be documented with respect to the initiation of antihypertensive medication and the proportion of patients achieving BP targets within 1 hour of treatment.
At completion of the 24h active treatment period, all patients will continue to receive standard stroke care and rehabilitation, and treating physicians will manage BP in the manner they feel is appropriate. Physicians will be encouraged to start oral antihypertensive therapy, administered via nasogastric feeding tube if necessary, on day 2. BP, HR and antihypertensive medication doses will continue to be monitored and recorded every 4 h for the first 48 h and then twice daily until discharge. Long-term goals for both patient groups after the active treatment period are a systolic BP of <140 mmHg, or <130 mmHg in those with diabetes, as per current stroke prevention and hypertension guidelines.
Imaging Procedures:
Baseline - Immediately prior to randomization and BP reduction, patients will undergo a standard non-contrast CT diagnostic brain scan. In the event of early neurological deterioration at any point, a repeat CT scan will be obtained immediately.
24 hour CT - All patients will have a repeat CT brain scan at 24±3 h, in order to assess for hematoma expansion and peri-hematoma edema volume.
48 hour MRI - At 48±12 h, patients will undergo MRI scanning, including a T1-weighted sagittal localizer, DWI, Gradient Recalled Echo (GRE)/Susceptibility Weighted Imaging (SWI), diffusion-weighted (DWI) and perfusion-weighted images (PWI).
Day 7 MRI Scan (Secondary Endpoint) - A repeat MRI will be obtained at 7±2 days to assess for new DWI lesion development and evolution of those identified at 24 hours.
Day 30 MRI Scan (Secondary Endpoint) - A repeat MRI will be obtained at 30±5 days to assess for new DWI lesion development and evolution of those identified at 24 hours and 7 days.
Clinical Assessments:
In Hospital - In addition to BP data, GCS and NIHSS scores will be collected in the event of early neurological deterioration. Both of these scores will also be recorded at the time of each MRI scan and at hospital discharge or transfer to alternate level of care, i.e. rehabilitation or long-term care facility. Discharge modified Rankin Scores (mRS) will also be recorded. Cognitive changes will be assessed with the Montreal Cognitive Assessment (MoCA) at the time of each MRI scan.
Follow-up (Day 30) - A standardized interview aimed at determining mortality and current residence of the patient (home/hospital/rehabilitation hospital/long-term care facility) will be administered at the time of the day 30 MRI. The NIHSS and MoCA scores will also be recorded, as will modified Rankin scale (mRS) scores. Quality of life will be assessed with the EQ-5D.
(Day 90) - This is the standard time point for measuring functional outcomes in stroke trials, as the bulk of neurological recovery occurs within that time frame. All neurological, functional and cognitive disability tests will be repeated at this time.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Brian Buck, MD
- Phone Number: 780-248-1188
- Email: bbuck@ualberta.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Recruiting
- University of Alberta
-
Principal Investigator:
- Brian Buck, MD
-
Contact:
- Brian Buck, MD
- Phone Number: 780-248-1188
- Email: bbuck@ualberta.ca
-
-
Ontario
-
Ottawa, Ontario, Canada, K1y 4e9
- Recruiting
- Ottawa Hospital Research Institute
-
Principal Investigator:
- Dar Dowlatshahi, MD
-
Contact:
- Dar Dowlatshahi
- Phone Number: 613-761-4709
- Email: ddowlat@toh.on.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Acute primary ICH demonstrated with CT scan, within 6 h of symptom onset.
- Two systolic BP measurements ≥140 mmHg recorded >2 min apart to qualify for enrolment.
- Onset ≤ 24 h prior to randomization
Exclusion Criteria:
- Contraindication to BP reduction i.e., severe arterial stenosis or high-grade stenotic valvular heart disease
- Indication for urgent BP reduction i.e., hypertensive encephalopathy, or aortic dissection
- Definite evidence that the ICH is secondary to underlying cerebral or vascular pathology, i.e., AVM, aneurysm, tumour, trauma, vasculitis, or hemorrhagic transformation of an ischemic infarct
- Previous ischemic stroke within 90 days of current event NB: Prior ICH is not an exclusion criterion
- Patients with suspected secondary cause of ICH.
- Planned surgical resection of hematoma NB: Extraventricular Drain placement is not an exclusion criterion
- Contraindication to CT perfusion imaging (i.e. contrast allergy, metformin use or Creatinine >160 μmol/l)
- Patients with pre-existing disability and dependence (defined as a pre-morbid modified Rankin Scale score ≥3) will be excluded
- Patients with life expectancy <6 months due to pre-morbid conditions/terminal illness
- Patients with known definite contraindications to MRI (pacemaker, ferrous metallic foreign body)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Target systolic BP <140mmHg
Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
|
Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
|
Active Comparator: Target systolic BP <180mmHg
Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
|
Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Diffusion-weighted imaging (DWI) lesion frequency
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative diffusion-weighted imaging (DWI) lesion frequency
Time Frame: 30 days post randomization
|
30 days post randomization
|
|
Absolute hematoma growth
Time Frame: 24 hours post randomization
|
24 hours post randomization
|
|
Functional disability as assessed by the Modified Rankin Scale
Time Frame: 90 days post randomization
|
Modified Rankin scale (0=no symptoms, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability, 6=dead)
|
90 days post randomization
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Cerebral Hemorrhage
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- Sympathomimetics
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Enalapril
- Labetalol
- Hydralazine
Other Study ID Numbers
- Version 2.0 (Sponsor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on labetalol/hydralazine/enalapril
-
University of AlbertaHeart and Stroke Foundation of Canada; Alberta Heritage Foundation for Medical...CompletedIntracerebral HemorrhageCanada
-
Tanta UniversityActive, not recruiting
-
Hamilton Health Sciences CorporationCompletedBlood Pressure | Stroke, Acute | Mechanical Thrombectomy | Endovascular Thrombectomy | Vessels; OcclusionCanada
-
New Mexico Cancer Care AllianceCompleted
-
Brigham and Women's HospitalCompletedChronic Hemodialysis (ESRD)United States
-
Shahid Sadoughi University of Medical Sciences...McMaster University; National Institute for Medical Research Development (NIMAD)Recruiting
-
Kaohsiung Veterans General Hospital.E-DA HospitalRecruitingMitral Regurgitation | Systolic Heart Failure Stage D (Disorder)Taiwan
-
Saint Thomas Hospital, PanamaCompletedHypertension, Pregnancy InducedPanama
-
University of ArkansasWithdrawnRectal Cancer
-
Dow University of Health SciencesCompletedPre-eclampsia | Hypertension, Pregnancy Induced | Hydralazine Adverse Reaction | Pre-eclampsia Superimposed Pre-existing HypertensionPakistan